- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.03. | UK's pricing watchdog rejects Alzheimer treatments for the second time | ||
| 07.03. | J&J drops Phase III MDD programme due to lack of efficacy | ||
| 07.03. | FDA approves scPharmaceuticals' Furoscix sNDA for oedema in CKD | ||
| 07.03. | The trillion-dollar opportunity in women's health | ||
| 07.03. | FDA ODD given to Plus Therapeutics' injectable radiotherapy | ||
| 07.03. | Understanding the rules on HPAPI containment in high potent manufacturing | ||
| 07.03. | Astellas and Yaskawa form JV for cell therapy product manufacture | ||
| 07.03. | Tumour-on-chip model could help discover pancreatic cancer therapies | ||
| 06.03. | Merck KGaA reports YE24 earnings growth amid SpringWorks acquisition talks | ||
| 06.03. | ITM targets US approval for radiopharmaceutical after Phase III readout | ||
| 06.03. | Project Optimus: The evolution of dose optimisation in oncology | ||
| 06.03. | Tris Pharma eyes approval after pain drug triumphs in second Phase III trial | ||
| 06.03. | TC BioPharm signs LoI to acquire ophthalmic pharma company | ||
| 06.03. | Novo Nordisk cuts Wegovy price through new direct-to-patient online pharmacy | ||
| 06.03. | Trimtech closes seed fund round to advance CNS therapeutics pipeline | ||
| 06.03. | Beyond compliance: The strategic role of PASS in rare disease therapy success | ||
| 06.03. | Realising the opportunities for growth in the European orphan drug market | ||
| 06.03. | Orphan drugs: How to avoid costly stock losses in Europe | ||
| 06.03. | FDA approves ARS' neffy 1mg for paediatric anaphylaxis | ||
| 05.03. | Biosimilars drive Sandoz growth ahead of unclear tariff effects in 2025 | ||
| 05.03. | Jazz Pharmaceuticals bids for Chimerix in $935m deal | ||
| 05.03. | Container Closure Integrity Testing (CCIT): What you need to know | ||
| 05.03. | Indonesia approves Antengene's Xpovio NDA for multiple indications | ||
| 05.03. | Asceneuron halts Alzheimer's trial adding to tau-targeting setbacks | ||
| 05.03. | WuXi Biologics introduces E coli expression system |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
